## Overall survival in patients with BRAF-mutant melanor binimetinib versus vemurafenib or encorafenib (COLUN randomised, phase 3 trial

Lancet Oncology, The 19, 1315-1327 DOI: 10.1016/s1470-2045(18)30497-2

**Citation Report** 

#	Article	IF	CITATIONS
3	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 743-771.		0
4	Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors. JAMA Network Open, 2019, 2, e198890.	5.9	96
5	Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Cancers, 2019, 11, 1176.	3.7	20
7	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, courseÂand management. European Journal of Cancer, 2019, 119, 97-106.	2.8	75
8	Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection. Frontiers in Medicine, 2019, 6, 140.	2.6	9
10	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer, 2019, 19, 665.	2.6	42
11	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports, 2019, 21, 76.	4.0	18
12	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. Oncologist, 2019, 24, e1197-e1211.	3.7	15
13	Targeted therapy for malignant melanoma. Current Opinion in Pharmacology, 2019, 46, 116-121.	3.5	19
14	A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein. Molecular Therapy - Nucleic Acids, 2019, 18, 727-738.	5.1	27
15	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 2019, 123, 58-71.	2.8	45
16	Novel Targets for the Treatment of Melanoma. Current Oncology Reports, 2019, 21, 97.	4.0	15
17	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers, 2019, 11, 1642.	3.7	47
18	The adjuvant treatment revolution for high-risk melanoma patients. Seminars in Cancer Biology, 2019, 59, 283-289.	9.6	40
19	BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers, 2019, 11, 1262.	3.7	99
20	Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. Cancers, 2019, 11, 1342.	3.7	22
21	Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression. International Journal of Molecular Sciences, 2019, 20, 4484.	4.1	18
22	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer. New England Journal of Medicine, 2019, 381, 1632-1643.	27.0	918

ATION REDO

#	Article	IF	CITATIONS
23	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 1884-1901.	1.2	394
24	Defining subpopulations of differential drug response to reveal novel target populations. Npj Systems Biology and Applications, 2019, 5, 36.	3.0	18
25	Targeted Therapy and Immunotherapy for Melanoma in Japan. Current Treatment Options in Oncology, 2019, 20, 7.	3.0	79
26	Early-phase clinical drug development of novel agents: a changing paradigm. Annals of Oncology, 2019, 30, 1033-1037.	1.2	5
27	Management of metastatic cutaneous melanoma: updates in clinical practice. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985166.	3.2	29
28	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open, 2019, 4, e000491.	4.5	140
29	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Frontiers in Immunology, 2019, 10, 990.	4.8	86
30	Reinduktion zielgerichteter Therapie beim metastasierten Melanom. JDDG - Journal of the German Society of Dermatology, 2019, 17, 483-487.	0.8	1
31	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New England Journal of Medicine, 2019, 381, 626-636.	27.0	909
32	Precision Medical Approaches to the Diagnoses and Management of Brain Metastases. Current Treatment Options in Oncology, 2019, 20, 49.	3.0	6
33	Design, synthesis, and anticancer evaluation of novel quinoline derivatives of ursolic acid with hydrazide, oxadiazole, and thiadiazole moieties as potent MEK inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 955-972.	5.2	50
34	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
35	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 1-29.		0
36	Encorafenib + binimetinib: a profile of their combined use in treating BRAF-mutated unresectable or metastatic melanoma. Drugs and Therapy Perspectives, 2019, 35, 151-159.	0.6	0
37	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. Clinical Pharmacokinetics, 2019, 58, 1029-1043.	3.5	6
38	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opinion on Drug Safety, 2019, 18, 381-392.	2.4	62
39	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
40	Evaluation of cutaneous adverse events of encorafenib and binimetinb: COMMENT on article by Graf etÂal Journal of the European Academy of Dermatology and Venereology, 2019, 33, 630-631.	2.4	0

#	Article	IF	CITATIONS
41	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 2019, 37, 1460-1469.	1.6	188
42	Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. European Journal of Cancer, 2019, 111, 8-11.	2.8	6
43	Rechallenge of targeted therapy in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2019, 17, 483-486.	0.8	13
44	Management of V600E and V600K BRAF-Mutant Melanoma. Current Treatment Options in Oncology, 2019, 20, 81.	3.0	28
45	Melanoma. Anti-Cancer Drugs, 2019, 30, 543-553.	1.4	1
46	Adjuvant systemic therapy in high-risk melanoma. Melanoma Research, 2019, 29, 358-364.	1.2	16
47	Systemic therapies for unresectable locoregional melanoma: a significant area of need. Melanoma Management, 2019, 6, MMT25.	0.5	6
48	Clinical Application of Next-Generation Sequencing–Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. Molecular Cancer Therapeutics, 2020, 19, 937-944.	4.1	14
49	Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. Anti-Cancer Drugs, 2019, 30, 1052-1054.	1.4	3
50	BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. Expert Opinion on Investigational Drugs, 2019, 28, 143-148.	4.1	16
51	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Review of Clinical Pharmacology, 2019, 12, 259-266.	3.1	44
52	Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma. Acta Oncológica, 2020, 59, 310-314.	1.8	5
53	Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. Clinical and Translational Oncology, 2020, 22, 900-907.	2.4	8
54	Principles of Targeted Therapy for Melanoma. Surgical Clinics of North America, 2020, 100, 175-188.	1.5	40
55	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer, 2020, 126, 523-530.	4.1	43
56	Image Guided Dermatologic Treatments. , 2020, , .		4
57	Synthetic lethality as an engine for cancer drug target discovery. Nature Reviews Drug Discovery, 2020, 19, 23-38.	46.4	295
58	Mitogenâ€activated protein kinase dependency in <i>BRAF</i> / <i>RAS</i> wildâ€type melanoma: A rationale for combination inhibitors. Pigment Cell and Melanoma Research, 2020, 33, 345-357.	3.3	2

		CITATION R	EPORT	
#	Article		IF	CITATIONS
59	The impact of current treatment modalities on the outcomes of patients with melanoma metastases: A systematic review. International Journal of Cancer, 2020, 146, 1479-1489	a brain	5.1	20
60	Brain malignancies: Clioblastoma and brain metastases. Seminars in Cancer Biology, 202	20, 60, 262-273.	9.6	208
61	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advan perspectives. Expert Review of Respiratory Medicine, 2020, 14, 367-383.	ces and new	2.5	21
62	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a random trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma. European Journal of Cancer, 2020, 126, 33-44.	ised phase 3	2.8	130
63	Novedades terapéuticas en dermatologÃa. Piel, 2020, 35, 4-9.		0.0	0
64	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mu Melanoma. Translational Oncology, 2020, 13, 275-286.	tated	3.7	13
65	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated Current Opinion in Oncology, 2020, 32, 79-84.	d melanoma.	2.4	25
66	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. Expert Anticancer Therapy, 2020, 20, 53-62.	Review of	2.4	6
67	Nongenetic Mechanisms of Drug Resistance in Melanoma. Annual Review of Cancer Biol 315-330.	ogy, 2020, 4,	4.5	18
68	Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adju Current Opinion in Oncology, 2020, 32, 85-90.	uvant setting.	2.4	8
69	Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. 0 2801.	Cancers, 2020, 12,	3.7	73
70	Real-world treatment practice in patients with advanced melanoma. Wspolczesna Onko 118-124.	logia, 2020, 24,	1.4	6
71	Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced serous ovarian carcinoma. Upsala Journal of Medical Sciences, 2020, 125, 325-329.	low-grade	0.9	8
73	Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib ar combination: two cases. Melanoma Research, 2020, 30, 519-523.	id trametinib	1.2	4
74	ESMO consensus conference recommendations on the management of metastatic mela auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448	noma: under the 3.	1.2	132
75	Molecular and immunological associations of elevated serum lactate dehydrogenase in r melanoma patients: A fresh look at an old biomarker. Cancer Medicine, 2020, 9, 8650-80	netastatic 661.	2.8	11
76	The concepts of rechallenge and retreatment in melanoma: A proposal for consensus de European Journal of Cancer, 2020, 138, 68-76.	finitions.	2.8	10
77	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated randomized phase 2 trial. Nature Medicine, 2020, 26, 1564-1568	melanoma: a	30.7	71

#	Article	IF	CITATIONS
78	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAFV600E/K</i> -mutant Solid Tumors. Clinical Cancer Research, 2020, 26, 5102-5112.	7.0	23
79	Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer Immunology Research, 2020, 8, 1114-1121.	3.4	9
80	Rapid BRAF Mutation Testing in Pigmented Melanomas. American Journal of Dermatopathology, 2020, 42, 343-348.	0.6	7
81	Targeted and immunotherapies in <i>BRAF</i> mutant melanoma: where we stand and what to expect. British Journal of Dermatology, 2021, 185, 253-262.	1.5	20
82	A Blue Light-Inducible CRISPR-Cas9 System for Inhibiting Progression of Melanoma Cells. Frontiers in Molecular Biosciences, 2020, 7, 606593.	3.5	13
83	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. Cancers, 2020, 12, 3456.	3.7	12
84	CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment. Pharmaceuticals, 2020, 13, 418.	3.8	28
85	The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future. International Journal of Molecular Sciences, 2020, 21, 9001.	4.1	8
86	Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984.	4.1	88
87	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
88	Hydroxynaphthalenecarboxamides and substituted piperazinylpropandiols, two new series of BRAF inhibitors. A theoretical and experimental study. Bioorganic Chemistry, 2020, 103, 104145.	4.1	8
89	Preclinical discovery and clinical development of encorafenib for the treatment of melanoma. Expert Opinion on Drug Discovery, 2020, 15, 1373-1380.	5.0	7
90	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Reports, 2020, 31, 107764.	6.4	69
91	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. Journal of Clinical Medicine, 2020, 9, 2430.	2.4	10
92	Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer, 2020, 6, 797-810.	7.4	169
93	Advances in the Systemic Treatment of Melanoma Brain Metastases. , 2020, , .		0
94	Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients. Cancers, 2020, 12, 3004.	3.7	3
95	Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib. European Journal of Cancer, 2020, 139, 37-40.	2.8	2

#	Article	IF	CITATIONS
96	Tyrosine kinase inhibitors for solid tumors in the past 20Âyears (2001–2020). Journal of Hematology and Oncology, 2020, 13, 143.	17.0	226
97	Treatment of Advanced Melanoma: Past, Present and Future. Life, 2020, 10, 208.	2.4	18
98	Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. Expert Opinion on Drug Safety, 2020, 19, 1229-1236.	2.4	3
99	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Research, 2020, 30, 465-471.	1.2	14
101	Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma. Melanoma Research, 2020, 30, 477-483.	1.2	5
103	B-Raf-Mutated Melanoma. , 2020, , .		Ο
104	Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma. International Journal of Molecular Sciences, 2020, 21, 9730.	4.1	15
105	Censored patients in Kaplan–Meier plots of cancer drugs: An empirical analysis of data sharing. European Journal of Cancer, 2020, 141, 152-161.	2.8	13
106	Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. Journal of Medicinal Chemistry, 2020, 63, 15883-15905.	6.4	21
107	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2020, 10, 571135.	2.8	2
108	miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma. Neoplasia, 2020, 22, 789-799.	5.3	9
110	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers, 2020, 12, 1176.	3.7	11
111	Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer. Facial Plastic Surgery, 2020, 36, 200-210.	0.9	7
112	BRAF mutation and its inhibitors in sarcoma treatment. Cancer Medicine, 2020, 9, 4881-4896.	2.8	26
113	MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. Journal of Neuropathology and Experimental Neurology, 2020, 79, 746-753.	1.7	4
114	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. Expert Opinion on Investigational Drugs, 2020, 29, 739-753.	4.1	2
115	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – A Potential Paradigm Shift in Management. Annals of Surgical Oncology, 2020, 27, 2188-2200.	1.5	4
116	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1, 482-492.	13.2	23

		CITATION RE	PORT	
#	Article		IF	CITATIONS
117	Neoadjuvant Therapy for Melanoma. Surgical Oncology Clinics of North America, 2020, 2	29, 445-453.	1.5	2
118	Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. Kid 2020, 2, 373-375.	ney Medicine,	2.0	5
119	Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Melanoma. Cancers, 2020, 12, 1500.	BrafV600E	3.7	9
120	Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Rep Literature Review. Targeted Oncology, 2020, 15, 407-410.	ort and	3.6	17
121	<p>Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Trea and MEK Inhibitors – Results of a Prospective Biomarker Study</p> . OncoTargets 2020, Volume 13, 5017-5032.	ted by BRAF and Therapy,	2.0	9
122	Pre-clinical modeling of cutaneous melanoma. Nature Communications, 2020, 11, 2858.		12.8	133
123	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Ca 2020, 41, 409-434.	are Medicine,	2.1	11
124	Incorporating traditional and emerging biomarkers in the clinical management of metast colorectal cancer: an update. Expert Review of Molecular Diagnostics, 2020, 20, 653-664	atic 4.	3.1	7
125	Combination of PDâ€1 inhibitor and targeted therapy in advanced <i>BRAF</i> V600Eâ€ with symptomatic brain metastases: a report of five cases. JDDG - Journal of the German Dermatology, 2020, 18, 901-904.	mutant melanoma Society of	0.8	1
126	Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therap Melanoma. Frontiers in Cell and Developmental Biology, 2020, 8, 486.	y in Metastatic	3.7	42
127	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase path and immune checkpoint inhibition - Update 2019. European Journal of Cancer, 2020, 13	1way inhibition 0, 126-138.	2.8	84
128	Targeting complex, adaptive responses in melanoma therapy. Cancer Treatment Reviews 101997.	s, 2020, 86,	7.7	8
129	The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoms Scientific Reports, 2020, 10, 4940.	a patients.	3.3	12
130	The discovery and development of binimetinib for the treatment of melanoma. Expert O Discovery, 2020, 15, 745-754.	pinion on Drug	5.0	25
131	Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted The Checkpoint Blockade: Are We Approaching a True Cure?. American Journal of Clinical De 2020, 21, 493-504.	rapy or Immune rmatology,	6.7	30
132	BRAF inhibition in melanoma is associated with the dysregulation of histone methylatior methyltransferases. Neoplasia, 2020, 22, 376-389.	and histone	5.3	14
133	Adjuvant Therapy for Cutaneous Melanoma. Surgical Oncology Clinics of North America, 455-465.	2020, 29,	1.5	1
134	Molecular therapeutic targets in non-small cell lung cancer. Expert Review of Anticancer 2020, 20, 647-661.	Therapy,	2.4	46

#	Article	IF	CITATIONS
135	A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report. Frontiers in Oncology, 2020, 10, 1056.	2.8	5
136	BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers, 2020, 12, 1823.	3.7	82
137	Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. Targeted Oncology, 2020, 15, 531-540.	3.6	12
138	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092521.	3.2	31
139	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precision Oncology, 2020, 4, 20-31.	3.0	19
140	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. Cancer Treatment Reviews, 2020, 88, 102060.	7.7	27
141	Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers, 2020, 12, 482.	3.7	112
142	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers, 2020, 12, 512.	3.7	15
143	An overview of binimetinib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2020, 21, 747-754.	1.8	8
144	RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. Neuro-Oncology Practice, 2020, 7, 369-375.	1.6	2
145	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. Journal of the National Cancer Institute, 2020, 112, 875-885.	6.3	20
146	Secondary histiocytic sarcoma with BRAF <sup>V600E</sup> mutation after Tâ€cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. Pediatric Blood and Cancer, 2020, 67, e28200.	1.5	12
147	<i> <scp>GNAQ</scp> </i> and <i> <scp>GNA</scp> 11 </i> mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. British Journal of Dermatology, 2020, 183, 928-939.	1.5	24
148	Encorafenib, binimetinib and cetuximab combined therapy for patients with <i>BRAFV600E</i> mutant metastatic colorectal cancer. Future Oncology, 2020, 16, 161-173.	2.4	9
149	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. Cells, 2020, 9, 417.	4.1	32
150	Nanosystems for Improved Targeted Therapies in Melanoma. Journal of Clinical Medicine, 2020, 9, 318.	2.4	30
151	Autophagy regulation as a promising approach for improving cancer immunotherapy. Cancer Letters, 2020, 475, 34-42.	7.2	32
152	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Experimental Hematology and Oncology, 2020, 9, 7.	5.0	11

# 154	ARTICLE Toward a More Precise Future for Oncology. Cancer Cell, 2020, 37, 431-442.	IF 16.8	CITATIONS
155	Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. Clinical Cancer Research, 2020, 26, 3803-3818.	7.0	21
156	Improvements in Clinical Outcomes for <i>BRAFV600E</i> -Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4435-4441.	7.0	17
157	Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970.	1.6	190
158	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treatment Reviews, 2020, 86, 101998.	7.7	25
159	Emerging strategies to treat rare and intractable subtypes of melanoma. Pigment Cell and Melanoma Research, 2021, 34, 44-58.	3.3	22
160	Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a realâ€world setting. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 105-115.	2.4	9
161	miR-942-5p promotes the proliferation and invasion of human melanoma cells by targeting DKK3. Journal of Receptor and Signal Transduction Research, 2021, 41, 180-187.	2.5	17
163	Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus. Histopathology, 2021, 78, 240-251.	2.9	9
164	First-line immunotherapy versus targeted therapy in patients with <i>BRAF</i> -mutant advanced melanoma: a real-world analysis. Future Oncology, 2021, 17, 689-699.	2.4	21
165	Prevalence of class l–III BRAF mutations among 114,662 cancer patients in a large genomic database. Experimental Biology and Medicine, 2021, 246, 31-39.	2.4	36
166	Patient preferences for treatment of advanced melanoma: impact of comorbidities. JDDG - Journal of the German Society of Dermatology, 2021, 19, 58-70.	0.8	7
167	Current Management of Melanoma. Updates in Surgery Series, 2021, , .	0.1	0
168	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology, 2021, 16, 37-46.	3.6	5
169	BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells. Cancer Letters, 2021, 499, 122-136.	7.2	13
170	Case series of <i>BRAF</i> â€mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy. Journal of Dermatology, 2021, 48, 397-400.	1.2	7
171	Advanced Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 111-128.	2.2	5
172	Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelinesa~†. Annals of Oncology, 2021, 32, 157-170.	1.2	65

# 173	ARTICLE Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma. Dermatologic	IF 1.7	CITATIONS
174	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology, 2021, 16, 47-57.	3.6	8
175	Biology of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 29-56.	2.2	40
176	Systematic review of BRAF/MEK inhibitorsâ€induced Severe Cutaneous Adverse Reactions (SCARs). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 607-614.	2.4	26
177	Alternative use of BRAF inhibitors in patients with metastatic melanoma unable to swallow pills. Journal of Oncology Pharmacy Practice, 2021, 27, 996-999.	0.9	2
178	Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129736.	2.4	38
179	ls single versus combination therapy problematic in the treatment of cutaneous melanoma?. Expert Review of Clinical Pharmacology, 2021, 14, 9-23.	3.1	5
182	Dabrafenib and Trametinib. , 2021, , 131-147.		0
183	New Therapies in Advanced Cutaneous Malignancies: Conclusions. , 2021, , 441-448.		1
184	Drug resistance in targeted cancer therapies with RAF inhibitors. , 2021, 4, 665-683.		9
185	Cell Proliferation Is Strongly Associated with the Treatment Conditions of an ER Stress Inducer New Anti-Melanoma Drug in Melanoma Cell Lines. Biomedicines, 2021, 9, 96.	3.2	5
186	Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermo-sifiliográficas, 2021, 112, 142-152.	0.4	2
188	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. Journal of Clinical Oncology, 2021, 39, 273-284.	1.6	254
189	Defining and Targeting BRAF Mutations in Solid Tumors. Current Treatment Options in Oncology, 2021, 22, 30.	3.0	25
190	Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma. Journal of Cutaneous Medicine and Surgery, 2021, 25, 364-370.	1.2	3
191	Efficacy of Targeted Radionuclide Therapy Using [1311]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. Cancers, 2021, 13, 1421.	3.7	5
192	BRAF Gene and Melanoma: Back to the Future. International Journal of Molecular Sciences, 2021, 22, 3474.	4.1	40
193	Circulating tumour DNA in patients with melanoma receiving targeted therapy. Lancet Oncology, The, 2021, 22, 291-293.	10.7	0

		CITATION REPORT		
#	Article		IF	CITATIONS
194	Recent advancements in melanoma management. Internal Medicine Journal, 2021, 51,	327-333.	0.8	4
195	Inhibition of FGFâ€FGFR and VEGFâ€VEGFR signalling in cancer treatment. Cell Prolifer e13009.	ation, 2021, 54,	5.3	76
196	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic N American Journal of Clinical Dermatology, 2021, 22, 301-314.	1elanoma.	6.7	18
197	First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?. JMIR Can	cer, 2021, 7, e29912.	2.4	4
198	A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab w MEK inhibitors for the treatment of BRAF-mutant advanced melanomaâ~†. ESMO Oper	rith BRAF plus 1, 2021, 6, 100050.	4.5	14
199	Relevance of body mass index as a predictor of systemic therapy outcomes in metasta analysis of the MelBase French cohort dataâ~†. Annals of Oncology, 2021, 32, 542-551	tic melanoma: 	1.2	13
200	Impact of novel systemic therapies on the firstâ€year costs of care for melanoma amo beneficiaries. Cancer, 2021, 127, 2926-2933.	ng Medicare	4.1	7
202	Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to in ductal carcinoma. PLoS ONE, 2021, 16, e0252314.	vasive breast	2.5	3
204	Complete response of brainstem metastasis in BRAF-mutated melanoma without stere radiosurgery after initiation of encorafenib and binimetinib. Melanoma Research, 2021 of Print, 393-396.	otactic , Publish Ahead	1.2	2
205	Recent Advances in Synthesis and Biological Assessment of Quinolineâ€Oxygen Heter ChemistrySelect, 2021, 6, 5148-5165.	ocycle Hybrids.	1.5	11
206	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Crossa longitudinal analysis using two large national registries. Cancer Medicine, 2021, 10, 38	ì€sectional and 362-3872.	2.8	17
207	Systemic Therapy for Head and Neck Skin Cancers. Face, 2021, 2, 121-130.		0.2	0
208	The role of regional chemotherapy for advanced limb melanoma in the era of potential systemic therapies. Melanoma Research, 2021, Publish Ahead of Print, 290-297.	y effective	1.2	2
209	Current management of melanoma patients with nodal metastases. Clinical and Experi Metastasis, 2022, 39, 181-199.	imental	3.3	8
210	Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. Journal of Dermatology, 2021, 141, 1317-1324.e1.	Investigative	0.7	9
211	Recent Advances in the Treatment of Melanoma. New England Journal of Medicine, 20.	21, 384, 2229-2240.	27.0	201
212	Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. OncoTargets a Volume 14, 3709-3719.	nd Therapy, 2021,	2.0	24
214	The role of immunotherapy and molecular‑targeted therapy in the treatment of mela Oncology Reports, 2021, 46, .	noma (Review).	2.6	14

#	Article	IF	CITATIONS
215	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2021, 11, 518.	2.5	8
216	Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 55.	3.0	4
217	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Frontiers in Oncology, 2021, 11, 670726.	2.8	26
218	Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600 melanoma patients. Annales De Dermatologie Et De Venereologie, 2022, 149, 32-38.	1.0	4
219	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung Cancer, 2021, 157, 21-29.	2.0	8
220	Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study. Cancer Management and Research, 2021, Volume 13, 5699-5709.	1.9	6
221	Advances in the discovery and development of melanoma drug therapies. Expert Opinion on Drug Discovery, 2021, 16, 1319-1347.	5.0	9
222	Recognition, Staging, and Management of Melanoma. Medical Clinics of North America, 2021, 105, 643-661.	2.5	4
223	A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. Journal of Thoracic Disease, 2021, 13, 4054-4062.	1.4	9
224	New systemic therapies for cutaneous melanoma: why, who and what. Italian Journal of Dermatology and Venereology, 2021, 156, 344-355.	0.2	2
225	Treatment of Advanced Metastatic Melanoma. Dermatology Practical and Conceptual, 2021, 11, 2021164S.	0.9	10
226	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	2.8	7
227	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Research, 2021, 81, 5230-5241.	0.9	9
228	Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1297-1305.	0.8	6
229	Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?. Meditsinskiy Sovet, 2021, , 48-63.	0.5	2
230	Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opinion on Drug Safety, 2022, 21, 107-119.	2.4	2
231	Hypertension Induced by Combination Therapy of Cancer: A Systematic Review and Meta-Analysis of Global Clinical Trials. Frontiers in Pharmacology, 2021, 12, 712995.	3.5	5
232	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. Expert Review of Precision Medicine and Drug Development, 2021, 6, 349-360.	0.7	0

#	Article	IF	CITATIONS
233	Gibt es eine Überbehandlung von Melanompatienten am Ende ihres Lebens? Ergebnisse einer multizentrischen Studie an 193 Melanompatienten. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1297-1306.	0.8	0
234	Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. Current Oncology, 2021, 28, 3537-3553.	2.2	5
235	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. Annales De Dermatologie Et De Venereologie, 2021, 148, 145-155.	1.0	4
236	Immune checkpoint inhibitors in melanoma. Lancet, The, 2021, 398, 1002-1014.	13.7	462
237	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. Cancers, 2021, 13, 4780.	3.7	8
238	Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India. Frontiers in Oncology, 2021, 11, 710585.	2.8	7
239	Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor. British Journal of Dermatology, 2021, , .	1.5	0
240	Dermatologic adverse events associated with targeted therapies for melanoma. Expert Opinion on Drug Safety, 2022, 21, 385-395.	2.4	0
241	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. Expert Review of Precision Medicine and Drug Development, 2021, 6, 19-29.	0.7	3
242	Immunotherapy for Melanoma. Advances in Experimental Medicine and Biology, 2020, 1244, 51-68.	1.6	41
243	Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models. Neuro-Oncology, 2021, 23, 770-782.	1.2	18
244	Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass. Melanoma Research, 2020, 30, 625-627.	1.2	5
245	Edoxaban prevented adverse effects including pyrexia and elevation of Dâ€dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAFâ€mutant melanoma. Journal of Dermatology, 2021, 48, 707-709.	1.2	3
246	Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report. Pteridines, 2020, 31, 151-157.	0.5	1
247	New drug: Binimetinib plus encorafenib for metastatic melanoma. Australian Prescriber, 2019, 42, 168-168.	1.0	2
248	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. Deutsches Ärzteblatt International, 2019, 116, 497-504.	0.9	15
249	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263.	2.8	62
250	Upregulation of microRNA‑31 is associated with poor prognosis in patients with advanced colorectal cancer. Oncology Letters, 2020, 19, 2685-2694.	1.8	6

#	Article	IF	CITATIONS
251	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	4.9	326
252	Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1150-1155.	4.9	5
253	Cutaneous Melanoma and Other Skin Cancers. UNIPA Springer Series, 2021, , 979-1007.	0.1	0
254	Evaluating Optimal Treatment for Melanoma: A Network Meta-Analysis. Chinese Journal of Plastic and Reconstructive Surgery, 2021, 3, 27-31.	0.3	0
255	Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. Current Oncology, 2021, 28, 3978-3986.	2.2	7
256	Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. Annals of Oncology, 2021, , .	1.2	5
257	PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma. Molecular Imaging and Biology, 2022, 24, 425-433.	2.6	3
258	Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta Oncológica, 2022, 61, 45-51.	1.8	3
259	BRAF-mutant Melanoma – The COLUMBUS Trial. European Oncology and Haematology, 2018, 14, 78.	0.0	0
261	Neue Arzneimittel 2018. , 2019, , 61-175.		1
262			
	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85.	1.8	1
263	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85. Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	1.8 0.1	1 0
263 264	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85.   Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.   Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.	1.8	1 0 0
263 264 265	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85.   Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.   Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.   Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.	1.8	1 0 0
263 264 265 266	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85.Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.Tumors: Melanoma. , 2020, , 1-11.	1.8	1 0 0 0
263 264 265 266	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85.   Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.   Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.   Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.   Tumors: Melanoma. , 2020, , 1-11.   Prevalence of <i>BRAF</i> V600 in glioma and use of <i>BRAF</i> Inhibitors in patients with	1.8	1 0 0 0 0 26
263 264 265 266 267	We shall overcome (drug resistance) some day. Oncotarget, 2019, 10, 84-85.   Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.   Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.   Skin Care During and After Radiotherapy and Anticancer Treatment. , 2020, , 1-16.   Tumors: Melanoma. , 2020, , 1-11.   Prevalence of <i>BRAF</i> V600 in glioma and use of <i>BRAF</i> Inhibitors in patients with <i>BRAF</i> V600 mutation-positive glioma: systematic review. Neuro-Oncology, 2022, 24, 528-540.   MAPK blockade, toxicities, pathogenesis and management. Current Opinion in Oncology, 2021, 33, 139-145.	1.8 0.1 1.2 2.4	1   0   0   0   0   20   26   3

#	Article	IF	CITATIONS
270	Glimmers of Hope—New Strategies for Overcoming Treatment Resistance in Patients with <i>BRAF</i> V600E-mutated Metastatic Colorectal Cancer. Oncology & Hematology Review, 2020, 16, 31.	0.2	1
271	Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase. Acta Dermato-Venereologica, 2020, 100, adv00174.	1.3	0
272	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
273	Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 760705.	3.7	3
275	Systemic Treatment in Advanced Melanoma. Updates in Surgery Series, 2021, , 167-174.	0.1	0
276	Clinicopathologic features and prognosis of epithelioid glioblastoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 1529-1539.	0.5	1
277	Tumors: Melanoma. , 2021, , 5260-5270.		0
278	Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. Frontiers in Oncology, 2021, 11, 771335.	2.8	15
279	Identification of a novel tumour microenvironmentâ€based prognostic biomarker in skin cutaneous melanoma. Journal of Cellular and Molecular Medicine, 2021, 25, 10990-11001.	3.6	8
280	Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor. Clinical Cancer Research, 2022, 28, 770-780.	7.0	10
281	Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nature Communications, 2021, 12, 7008.	12.8	22
282	Immunotherapy for Melanoma. Advances in Experimental Medicine and Biology, 2021, 1342, 81-111.	1.6	7
283	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. Oncologist, 2022, 27, e463-e470.	3.7	7
284	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert Review of Anticancer Therapy, 2022, 22, 17-25.	2.4	7
285	LC3 and NLRC5 interaction inhibits NLRC5-mediated MHC class I antigen presentation pathway in endometrial cancer. Cancer Letters, 2022, 529, 37-52.	7.2	18
286	Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights. Current Opinion in Oncology, 2022, 34, 115-122.	2.4	4
287	Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines. Npj Systems Biology and Applications, 2022, 8, 2.	3.0	0
288	Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers. European Journal of Medicinal Chemistry, 2022, 228, 114040.	5.5	5

#	Article	IF	CITATIONS
289	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. Biomedicines, 2022, 10, 284.	3.2	2
290	Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 1837-1849.	4.2	2
292	Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells. Frontiers in Oncology, 2022, 12, 794216.	2.8	10
293	Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management. Current Oncology Reports, 2022, 24, 265.	4.0	2
294	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. Cancer Treatment Reviews, 2022, 104, 102340.	7.7	21
295	The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. Cancers, 2022, 14, 777.	3.7	3
296	Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. Journal of Clinical Medicine, 2022, 11, 828.	2.4	10
297	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. Clinical Journal of Gastroenterology, 2022, 15, 413-418.	0.8	7
298	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.9	3
301	Encorafenib plus binimetinib in patients with <i>BRAF</i> <sup>V600</sup> -mutant non-smallÂcell lung cancer: phase II PHAROS study design. Future Oncology, 2022, 18, 781-791.	2.4	9
302	Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with <i>NRAS</i> -mutant Melanoma. Clinical Cancer Research, 2022, 28, 3002-3010.	7.0	18
303	The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response. PLoS Computational Biology, 2022, 18, e1009919.	3.2	4
304	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell Reports, 2022, 39, 110634.	6.4	10
305	Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
306	Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer. Critical Reviews in Oncology/Hematology, 2022, 173, 103646.	4.4	3
307	A protocol for phase II study investigating the safety and efficacy of TM5614 in combination with nivolumab in the treatment of unresectable malignant melanoma. Medicine, Case Reports and Study Protocols, 2021, 2, e0197.	0.1	0
308	Can Systems Biology Advance Clinical Precision Oncology?. Cancers, 2021, 13, 6312.	3.7	10
332	Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors. European Journal of Dermatology, 2019, 29, 107-108.	0.6	1

#	Article	IF	CITATIONS
334	The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance. Frontiers in Molecular Biosciences, 2022, 9, 864302.	3.5	6
335	A Novel Risk Model Based on Autophagy-Related LncRNAs Predicts Prognosis and Indicates Immune Infiltration Landscape of Patients With Cutaneous Melanoma. Frontiers in Genetics, 2022, 13, 885391.	2.3	7
336	Evolving Treatment Approaches to Mucosal Melanoma. Current Oncology Reports, 2022, 24, 1261-1271.	4.0	7
337	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clinical Cancer Research, 2022, 28, 4618-4628.	7.0	37
338	Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents. American Journal of Clinical Dermatology, 2022, 23, 523-545.	6.7	2
339	Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy. Case Reports in Oncology, 0, , 469-472.	0.7	1
340	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. Oral and Maxillofacial Surgery Clinics of North America, 2022, 34, 315-324.	1.0	2
343	Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. Cancer Research, 2022, 82, 2552-2564.	0.9	6
344	Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 2022, 13, 450-455.	0.4	11
345	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. Lung Cancer, 2022, 169, 102-114.	2.0	8
346	A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. Cancer Science, 0, , .	3.9	4
348	Locoregionally Advanced, BRAF V600L–Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of <i>BRAF</i> and <i>MEK</i> Inhibitors. JCO Precision Oncology, 2022, , .	3.0	0
349	Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis. European Journal of Endocrinology, 2022, 187, 185-196.	3.7	1
350	Three cases of malignant melanoma with rhabdomyolysis during combination therapy of dabrafenib and trametinib. Skin Cancer, 2022, 37, 16-21.	0.0	0
351	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 0, 13, .	4.8	6
352	COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With <i>BRAF</i> V600–Mutant Melanoma. Journal of Clinical Oncology, 2022, 40, 4178-4188.	1.6	57
353	Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. Cancers, 2022, 14, 3587.	3.7	6
354	What, if Any, Role Is There for BRAF-Targeted Therapy in <i>BRAF</i> -Mutant Melanoma?. Journal of Clinical Oncology, 2022, 40, 4161-4165.	1.6	6

#	Article	IF	CITATIONS
355	Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice. Melanoma Research, 0, Publish Ahead of Print, .	1.2	1
356	State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain. Neurosurgical Review, 2022, 45, 3119-3138.	2.4	1
357	Targeting Melanin in Melanoma with Radionuclide Therapy. International Journal of Molecular Sciences, 2022, 23, 9520.	4.1	5
358	Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.	4.0	4
359	Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	5
360	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2022, 35, 554-572.	3.3	3
361	Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study. Frontiers in Oncology, 0, 12, .	2.8	0
362	Vulvovaginal melanoma. , 2023, , 279-304.		0
363	Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Cancer Treatment Reviews, 2022, 110, 102463.	7.7	10
364	Conquering oncogenic KRAS and its bypass mechanisms. Theranostics, 2022, 12, 5691-5709.	10.0	1
365	Substanzen gegen molekulare Zielstrukturen. Springer Reference Medizin, 2022, , 1-14.	0.0	0
366	Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i> -Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134. Journal of Clinical Oncology, 2023, 41, 186-197.	1.6	140
367	Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?. Biomedicines, 2022, 10, 2424.	3.2	4
368	Novel Therapies in Clinical Development for Advanced Disease. , 0, , .		0
370	ä,€è^¬ç <b>¤</b> ₄団法人日本皮膚æ,ªæ€§è«çĩå¦ä¼šã€€æ,ªæ€§é»'色è«ï¼îāf¡ãf©ãfŽãf¼ãfžï¼‰è–	<sup>຺</sup> ¬ç‱©ç™	⁴,æ9•ã®æ‰<
371	Targeted Therapy and Immunotherapy in Melanoma. Dermatologic Clinics, 2023, 41, 65-77.	1.7	14
372	Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. Journal of Personalized Medicine, 2022, 12, 1746.	2.5	5
373	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	17.0	59

#	Article	IF	CITATIONS
374	Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma. Cancers, 2022, 14, 4930.	3.7	7
377	Clinical associations and genetic interactions of oncogenic BRAF alleles. PeerJ, 0, 10, e14126.	2.0	0
378	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. , 2022, 240, 108301.		9
379	Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer. European Journal of Pharmaceutical Sciences, 2023, 180, 106311.	4.0	2
380	Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study. International Journal of Clinical Oncology, 2023, 28, 139-144.	2.2	2
381	Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. Advances in Protein Chemistry and Structural Biology, 2023, , 179-201.	2.3	4
382	High-Throughput Functional Evaluation of <i>MAP2K1</i> Variants in Cancer. Molecular Cancer Therapeutics, 2023, 22, 227-239.	4.1	3
383	Targeted Therapy for Melanomas Without BRAF V600 Mutation. Current Oncology Reports, 2022, 24, 1873-1881.	4.0	3
384	Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial. BMJ Open, 2022, 12, e063700.	1.9	0
385	Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanoma. Oncology Letters, 2022, 25, .	1.8	9
386	BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers, 2023, 15, 141.	3.7	14
387	Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers, 2023, 15, 31.	3.7	1
388	Discovery of Novel 1,2,4â€Oxadiazolyl Triazole Hybrids as Bâ€Raf Inhibitors for the Treatment of Melanoma. ChemistrySelect, 2022, 7, .	1.5	1
389	Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Network Open, 2022, 5, e2245269.	5.9	19
390	Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy. Acta Oncológica, 2023, 62, 62-69.	1.8	5
391	PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	8
392	Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma. Journal of the European Academy of Dermatology and Venereology, 2023, 37, .	2.4	0
393	Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. BMC Health Services Research, 2023, 23, .	2.2	3

#	Article	IF	CITATIONS
394	Phytochemical Constituents and Derivatives of Cannabis sativa; Bridging the Gap in Melanoma Treatment. International Journal of Molecular Sciences, 2023, 24, 859.	4.1	8
395	Severe colitis in patients with melanoma treated with <scp>BRAF</scp> / <scp>MEK</scp> inhibitors. Alimentary Pharmacology and Therapeutics, 2023, 57, 792-799.	3.7	3
396	Surgical treatment options in a patient with borderline resectable tumour – a case report of a 54-year-old patient with locally advanced melanoma. Postepy Dermatologii I Alergologii, 2023, 40, 178-180.	0.9	0
397	Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open, 2023, 8, 100788.	4.5	22
398	Nebenwirkungen und deren Management. , 2022, , 121-146.		0
399	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
400	Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines. Translational Medicine Communications, 2023, 8, .	1.4	2
401	Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study. Cancers, 2023, 15, 1426.	3.7	0
402	Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene. Melanoma Research, 2023, 33, 247-251.	1.2	3
403	Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets. Translational Lung Cancer Research, 2023, 12, 707-718.	2.8	2
405	How have immune checkpoint inhibitors transformed melanoma treatment?. Trends in Urology & Men's Health, 2023, 14, 26-30.	0.4	0
406	Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. Cancer Research Communications, 2023, 3, 821-829.	1.7	9
407	Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. , 2023, 11, e005828.		3
408	Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An <i>In Vivo</i> – <i>In Vitro</i> – <i>In Silico</i> Approach. Molecular Pharmaceutics, 0, , .	4.6	6
409	N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer. Cell Reports Medicine, 2023, 4, 101002.	6.5	3
410	Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. Clinical Cancer Research, 2023, 29, 2753-2760.	7.0	19
411	Targeted therapy. , 2023, , 205-411.		0
412	Management of cutaneous melanoma in Australia: aÂnarrative review. Medical Journal of Australia, 2023, 218, 426-431.	1.7	3

#	Article	IF	CITATIONS
413	A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition. Investigational New Drugs, 2023, 41, 365-370.	2.6	1
414	Realâ€world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy. Pharmacoepidemiology and Drug Safety, 2023, 32, 988-1000.	1.9	1
415	Evolving Management of Stage IV Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2023, , .	3.8	2
416	Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2023, , .	3.8	14
417	Effect of target therapy with BRAF and MEK inhibitors on the immune system in metastatic melanoma. Onkologie (Czech Republic), 2023, 17, 108-112.	0.1	0
418	Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology, 2023, 92. 15-28.	2.3	6
419	A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma. Investigational New Drugs, 2023, 41, 551-555.	2.6	1
420	Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With <i>BRAF</i> <sup>V600</sup> -Mutant Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2023, 41, 3700-3711.	1.6	8
421	Curcumin Enhances the Anticancer Effects of Binimetinib on Melanoma Cells by Inducing Mitochondrial Dysfunction and Cell Apoptosis with Necroptosis. Annals of Dermatology, 2023, 35, 217.	0.9	0
422	Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies. Cancers, 2023, 15, 3126.	3.7	1
423	A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Frontiers in Oncology, 0, 12, .	2.8	1
424	Targeted therapeutic strategies for melanoma. Chinese Medical Journal, 2023, 136, 2923-2930.	2.3	0
425	Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis. Pharmaceuticals, 2023, 16, 935.	3.8	0
426	Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma. European Journal of Health Economics, 0, , .	2.8	1
428	[1,2,4]triazolo[4,3-a]quinoxaline as Novel Scaffold in the Imiqualines Family: Candidates with Cytotoxic Activities on Melanoma Cell Lines. Molecules, 2023, 28, 5478.	3.8	1
429	A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer, 2023, 183, 107313.	2.0	0
430	Prognosis in stageÂll melanoma of the head and neck depends on the histological subtype. JDDG - Journal of the German Society of Dermatology, 2023, 21, 1137-1146.	0.8	1
431	Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis. Cancers, 2023, 15, 3754.	3.7	2

#	Article	IF	CITATIONS
432	First <i>N</i> â€Functionalization of 4â€Nitrosoâ€1 <i>H</i> â€Pyrazoles Using Monofunctional and Bifunctional Alkylating Agents. ChemistrySelect, 2023, 8, .	1.5	0
433	Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i> -Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of Clinical Oncology, 2023, 41, 4621-4631.	1.6	3
434	A Theranostic Approach to Imaging and Treating Melanoma with 203Pb/212Pb-Labeled Antibody Targeting Melanin. Cancers, 2023, 15, 3856.	3.7	1
435	Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. Melanoma Research, 2023, 33, 406-416.	1.2	1
436	Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of Clinical Oncology, 2023, 41, 4794-4820.	1.6	15
437	Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers. Xenobiotica, 2023, 53, 339-356.	1.1	2
438	To Inhibit or Not to Inhibit MEK With BRAF Inhibitors: Is That the Question?. Journal of Clinical Oncology, 0, , .	1.6	0
439	Biomarkers to guide immunomodulatory treatment: where do we stand?. Expert Review of Molecular Diagnostics, 2023, 23, 945-958.	3.1	0
440	Probabilistic learning of treatment trees in cancer. Annals of Applied Statistics, 2023, 17, .	1.1	0
441	The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma. Cancers, 2023, 15, 4587.	3.7	0
442	Physiologically based pharmacokinetic modelling to predict drug–drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors. Xenobiotica, 2023, 53, 366-381.	1.1	2
444	Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM. EBioMedicine, 2023, 96, 104774.	6.1	7
445	COLUMBUS-AD: phase III study of adjuvant encorafenibÂ+Âbinimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. Future Oncology, 2023, 19, 2017-2027.	2.4	2
446	Review of pharmacoeconomic studies of melanoma treatment for the period 2018–2023. Ûžno-Rossijskij žurnal TerapevtiÄeskoj Praktiki, 2023, 4, 36-44.	0.3	0
447	Targeted Treatments for Cutaneous Melanoma. , 2023, , 1787-1800.		0
448	Unexpected and Rare Sites of Metastasis in Oncologic Patients. Journal of Clinical Medicine, 2023, 12, 6447.	2.4	0
449	Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations. Clinical and Translational Science, 2023, 16, 2675-2686.	3.1	0
450	Die Prognose des Melanoms im Kopfâ€Halsâ€Bereich im Stadium II hägt vom histologischen Subtyp ab. JDDG - Journal of the German Society of Dermatology, 2023, 21, 1137-1147.	0.8	0

ARTICLE IF CITATIONS Sustained improved survival of patients with metastatic melanoma after the introduction of 451 2.8 1 anti-PD-1-based therapies. European Journal of Cancer, 2023, 195, 113392. Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after 2.8 immune checkpoint inhibitors. Frontiers in Oncology, 0, 13, . Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF 453 2.8 0 V600 mutated melanoma receiving targeted therapy. European Journal of Cancer, 2024, 196, 113425. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in 454 NRAS-Mutated Melanoma. Cancers, 2023, 15, 5521. <scp>BRAF</scp> and <scp>MEK</scp> inhibitor combinations induce potent molecular and immunological effects in <scp>NRAS</scp>â€mutant melanoma cells: Insights into mode of action and 455 5.1 1 resistance mechanisms. International Journal of Cancer, 2024, 154, 1057-1072. Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data. Biomedicines, 2023, 11, 3.2 3264. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapyâ€"What Can Be Learned From 457 1.30 Progression?. Clinical Nuclear Medicine, 0, , . Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative 458 2.0 Literature Review. Healthcare (Switzerland), 2024, 12, 105. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway 459 0 4.1 across Cancers. International Journal of Molecular Sciences, 2024, 25, 624. Modelling adaptive therapy for tumor using reaction-diffusion equation. AIP Conference Proceedings, 0.4 2024,,. Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence. Current 461 2.4 1 Opinion in Oncology, 2024, 36, 69-73. Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells. Cancers, 2024, 16, 470. Metabolic Profiling to Assess Response to Targeted and Immune Therapy in Melanoma. International 463 4.1 0 Journal of Molecular Sciences, 2024, 25, 1725. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic 464 4.5 <i>BRAF</i>-Mutated Thyroid Cancer in Japan. Thyroid, 0, , . Longâ€term survival with systemic therapy in the last decade: Can melanoma be cured?. Journal of 465 1.2 0 Dermatology, 2024, 51, 343-352. Tumoren der Haut., 2024, , 945-962. Primary Cutaneous Melanomaâ€"Management in 2024. Journal of Clinical Medicine, 2024, 13, 1607. 467 2.4 0